InnoCan Pharma Corporation
INNPD
$12.53
-$0.39-3.02%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 18.20% | 61.49% | 115.55% | 192.24% | 271.49% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 18.20% | 61.49% | 115.55% | 192.24% | 271.49% |
| Cost of Revenue | 36.66% | 40.31% | 93.68% | 158.30% | 236.93% |
| Gross Profit | 16.15% | 64.36% | 118.61% | 196.52% | 275.76% |
| SG&A Expenses | 5.12% | 36.28% | 85.09% | 123.05% | 167.99% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.94% | 32.72% | 75.75% | 112.09% | 153.06% |
| Operating Income | 111.44% | 112.11% | 67.20% | 71.69% | 33.35% |
| Income Before Tax | 128.66% | 153.96% | 122.79% | 107.23% | 25.72% |
| Income Tax Expenses | 1.19% | 169.87% | 451.87% | 134,300.00% | 92,500.00% |
| Earnings from Continuing Operations | 90.13% | 121.53% | 93.83% | 78.14% | -5.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -4.02% | -122.65% | -247.02% | -295.29% | -483.25% |
| Net Income | 63.69% | 87.51% | 60.98% | 48.19% | -37.12% |
| EBIT | 111.44% | 112.11% | 67.20% | 71.69% | 33.35% |
| EBITDA | 112.83% | 113.17% | 67.84% | 72.31% | 33.71% |
| EPS Basic | 66.98% | 88.72% | 63.39% | 51.11% | -30.59% |
| Normalized Basic EPS | 71.42% | 93.03% | 68.10% | 60.18% | -20.37% |
| EPS Diluted | 66.98% | 88.72% | 63.39% | 51.11% | -27.31% |
| Normalized Diluted EPS | 71.42% | 93.03% | 68.10% | 60.18% | -20.37% |
| Average Basic Shares Outstanding | 7.01% | 8.85% | 8.87% | 8.77% | 7.43% |
| Average Diluted Shares Outstanding | 7.01% | 8.85% | 8.87% | 8.77% | 7.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |